S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in

BioCryst Pharmaceuticals Stock Forecast, Price & News

+0.31 (+2.96 %)
(As of 02/26/2021 12:00 AM ET)
Today's Range
Now: $10.78
50-Day Range
MA: $9.49
52-Week Range
Now: $10.78
Volume4.89 million shs
Average Volume7.30 million shs
Market Capitalization$1.90 billion
P/E RatioN/A
Dividend YieldN/A
BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
BioCryst Pharmaceuticals logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:BCRX
Phone(919) 859-1302
Year FoundedN/A



Sales & Book Value

Annual Sales$48.83 million
Book Value$0.26 per share


Net Income$-108,900,000.00
Net Margins-233.45%


Market Cap$1.90 billion
Next Earnings Date5/5/2021 (Estimated)


Overall MarketRank

1.12 out of 5 stars

Medical Sector

918th out of 1,962 stocks

Biological Products, Except Diagnostic Industry

120th out of 177 stocks

Analyst Opinion: 1.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
+0.31 (+2.96 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions

Is BioCryst Pharmaceuticals a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BioCryst Pharmaceuticals stock.
View analyst ratings for BioCryst Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than BioCryst Pharmaceuticals?

Wall Street analysts have given BioCryst Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioCryst Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is BioCryst Pharmaceuticals' next earnings date?

BioCryst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for BioCryst Pharmaceuticals

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its quarterly earnings results on Wednesday, February, 24th. The biotechnology company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.09. BioCryst Pharmaceuticals had a negative trailing twelve-month return on equity of 328.70% and a negative net margin of 233.45%.
View BioCryst Pharmaceuticals' earnings history

How has BioCryst Pharmaceuticals' stock price been impacted by Coronavirus?

BioCryst Pharmaceuticals' stock was trading at $2.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BCRX stock has increased by 316.2% and is now trading at $10.78.
View which stocks have been most impacted by COVID-19

What price target have analysts set for BCRX?

10 Wall Street analysts have issued 1-year price objectives for BioCryst Pharmaceuticals' stock. Their forecasts range from $6.00 to $14.00. On average, they anticipate BioCryst Pharmaceuticals' stock price to reach $10.71 in the next twelve months. This suggests that the stock has a possible downside of 0.6%.
View analysts' price targets for BioCryst Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the following people:
  • Jon P. Stonehouse, President, Chief Executive Officer & Director
  • Anthony Doyle, Chief Financial Officer & Senior Vice President
  • William P. Sheridan, Chief Medical Officer & Senior Vice President
  • Alane P. Barnes, Secretary, Chief Legal Officer & Senior VP
  • Megan Sniecinski, Chief Business Officer & Senior Vice President

What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO?

2 employees have rated BioCryst Pharmaceuticals CEO Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among BioCryst Pharmaceuticals' employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of BioCryst Pharmaceuticals' key competitors?

What other stocks do shareholders of BioCryst Pharmaceuticals own?

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.21%), Northern Trust Corp (1.17%), Nuveen Asset Management LLC (0.94%), Renaissance Technologies LLC (0.73%), Charles Schwab Investment Management Inc. (0.66%) and Voloridge Investment Management LLC (0.59%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Anthony Doyle, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski, Steve Aselage and Thomas R Staab II.
View institutional ownership trends for BioCryst Pharmaceuticals

Which major investors are selling BioCryst Pharmaceuticals stock?

BCRX stock was sold by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, Credit Suisse AG, Victory Capital Management Inc., Barclays PLC, Pura Vida Investments LLC, SG Americas Securities LLC, Edge Wealth Management LLC, and Formidable Asset Management LLC.
View insider buying and selling activity for BioCryst Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying BioCryst Pharmaceuticals stock?

BCRX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Voloridge Investment Management LLC, BlackRock Inc., North Star Investment Management Corp., Silverarc Capital Management LLC, Price T Rowe Associates Inc. MD, Los Angeles Capital Management LLC, and Golden Green Inc.. Company insiders that have bought BioCryst Pharmaceuticals stock in the last two years include Alane P Barnes, Anthony Doyle, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski, and Steve Aselage.
View insider buying and selling activity for BioCryst Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioCryst Pharmaceuticals' stock price today?

One share of BCRX stock can currently be purchased for approximately $10.78.

How much money does BioCryst Pharmaceuticals make?

BioCryst Pharmaceuticals has a market capitalization of $1.90 billion and generates $48.83 million in revenue each year. The biotechnology company earns $-108,900,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis.

How many employees does BioCryst Pharmaceuticals have?

BioCryst Pharmaceuticals employs 140 workers across the globe.

What is BioCryst Pharmaceuticals' official website?

The official website for BioCryst Pharmaceuticals is www.biocryst.com.

Where are BioCryst Pharmaceuticals' headquarters?

BioCryst Pharmaceuticals is headquartered at 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703.

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at (919) 859-1302 or via email at [email protected]

This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.